BioMarin submits clinical trial application with MHRA for Batten disease drug
The investigational recombinant human tripeptidyl peptidase 1, BMN-190, is being developed as a medication for a form of Batten disease called neuronal ceroid lipofuscinosis type 2 (NCL-2). The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.